Patrice A. Lee

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests

Patrice A. Lee has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

Anurag Singh
Pfizer Boulder Research and Development, Boulder, Colorado. 11
123 shared publications
Dylan P. Hartley
Pfizer Boulder Research and Development, Boulder, Colorado. 11
123 shared publications
Eric N. Brown
Pfizer Boulder Research and Development, Boulder, Colorado. 11
123 shared publications
Gang Feng
Pfizer Early Clinical Development, Cambridge, Massachusetts. 12
123 shared publications
John J. Gaudino
Pfizer Boulder Research and Development, Boulder, Colorado. 11
123 shared publications
Micaela B. Reddy
Pfizer Inc San Diego California USA
123 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S1. Cell lines used for cell-based pERK assays in Figure 1A
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S1. Cell lines used for cell-based pERK assays in Figure 1A
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S2. X-ray crystallography data collection and refinement statistics
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S2. X-ray crystallography data collection and refinement statistics
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S4. Patient PK profiles for PF-07799933.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S4. Patient PK profiles for PF-07799933.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Supplementary Methods, References
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Methods from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Supplementary Methods, References
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S5. Preliminary mutation analysis
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
by Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, et al.
Table S5. Preliminary mutation analysis

Show all